A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT06973668
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Phase 2
Not yet recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia (SLL)
- Interventions
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06967610
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Multi-center MRD Registry for Inflammatory Breast Cancer
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT06966050
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Phase 2
Not yet recruiting
- Conditions
- Neoadjuvant TreatmentThyroid Cancer
- Interventions
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06959511
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT06959550
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase Ib/II Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
Phase 1
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06959537
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- IvonescimabClear Cell Renal Carcinoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06940518
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Mediterranean Diet Intervention Among Men at LBJ Hospital With Prostate Cancer
Not Applicable
Not yet recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT06935097
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Phase 1
Not yet recruiting
- Conditions
- Myeloid Malignancies
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT06930651
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling Device
Not yet recruiting
- Conditions
- Colon Cancer
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06927011
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath